OBJECTIVES: Our objectives were to understand patient experience with and utilization of manufacturer-sponsored patient support programs for type 2 diabetes (T2DM) injectable therapy. METHODS: Data for these analyses were drawn from a larger cross-sectional survey evaluating treatment adherence and persistence among T2DM patients in the US age ≥18 who had been prescribed an injectable medication. Patients were recruited from a general-population on-line panel, and recruitment was stratified by medication and discontinuation status. Analyses are limited to the 3 medications for which ≥25 respondents reported using the corresponding patient support program: exenatide once weekly, liraglutide, insulin glargine.  Proportions were calculated using a drop-out weighting method.  RESULTS: Bydureon Steady Support (BSS) was utilized by 26% of exenatide once weekly patients (51/200), 14% of liraglutide patients (83/598) utilized Victoza Care (VC), and 10% of insulin glargine patients 48/488) utilized Lantus Connection (LC).  Those without previous injection experience were more likely to use a support program.  For 67% of patients using any program, the corresponding medication was the first injectable taken. The proportion who rated their program as extremely useful (6 or 7 on a 7-point scale) was 57% for BSS, 54% for VC, and 68% for LC. Overall, 49% reported using their program for 6 months or longer.  Length of utilization was highest for LC with 31% reporting using the program for ≥1 yr.  The program components most commonly used were educational materials (used by 75%), coupons (43%), telephonic support (31%), and medication reminders (8%).  Use of educational materials was highest for LC, use of coupons was highest for VC, and use of telephonic support and reminders was highest for BSS. CONCLUSIONS: Although the minority of patients reported using these patient-support programs, those who did use them reported high levels of satisfaction and relatively long engagement.